A Phase 2 interventional study of Tenecteplase in Ischemic Stroke, sponsored by General Hospital of Shenyang Military Region. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-01.
Sponsored by General Hospital of Shenyang Military Region · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies testing tenecteplase in Ischemic Stroke — 32 open to participants now, 32 under way, 25 of them phase 3. Tenecteplase · Ischemic Stroke.
Among the 59 studies testing tenecteplase in Ischemic Stroke, this one is the 53rd largest by planned enrollment, is one of 11 that started in 2026, is one of 10 in phase 2, reaches primary completion later than 13 of the 31 other live ones, and was the 50th registered.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
Browse Ischemic Stroke studies →32 of the 59 studies testing tenecteplase in Ischemic Stroke are open now, in 12 countries. Recruiting first, the newest first:
The First Affiliated Hospital of Zhengzhou University · Sites in China
Ages 18+
Yongjun Wang · Sites in China
Ages 18+
Shandong Provincial Hospital · Sites in China
Ages 18+
First Affiliated Hospital of Guangxi Medical University · Sites in China
Ages 18+
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18+
By country, each count listing its studies:
Tenecteplase: first FDA approval 2000 (TNKASE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 16 · Phase 3 43 · Phase 4 5
First in 2012; this study’s year is marked. 11 started in 2026.
This study's planned enrollment of 120 is close to the median of 120 across 1,788 interventional studies indexed under Ischemic Stroke.
Median enrollment 466 across the 59 interventional studies. Of the 22 that completed or were terminated, 1 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 59 have an industry lead sponsor. The 10 most frequent:
General Hospital of Shenyang Military Region is the lead sponsor of 78 studies on the registry; 33 are open to participants now.
34 studies in Ischemic Stroke by General Hospital of Shenyang Military Region: 16 open now, 16 under way, 1 of them phase 3. Of 17 finished, 0 (0%) have results posted.
Among the 34 studies in Ischemic Stroke by General Hospital of Shenyang Military Region, this one is the 16th largest by planned enrollment of the 27 interventional ones that give a count, is one of 5 that started in 2026, is one of 6 in phase 2, reaches primary completion later than 11 of the 15 other live ones, and was the 32nd registered.
General Hospital of Shenyang Military Region’s Ischemic Stroke studies by the year they started, since 2016.
7 of the studies testing tenecteplase in Ischemic Stroke that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06658197Phase 3Xuanwu Hospital, BeijingEfficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion Stroke | 2026-12-01 |
| NCT06954155Phase 3Beijing Tiantan HospitalTenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-BEYOND | 2027-02-28 |
| NCT07047014Phase 3Beijing Tiantan HospitalAdvancing Reperfusion Therapy for Ischemic Stroke (ARTS): Tenecteplase in Medium Vessel Occlusion (MeVO) for Acute Ischemic Stroke | 2027-03-30 |
| NCT07073469Phase 3Second Affiliated Hospital, School of Medicine, Zhejiang UniversityTenecteplase in ReperfUsion Therapy for Posterior Circulation Stroke With Extended Time Window: the TRUST Trial | 2027-08-01 |
| NCT07201688Phase 3CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.Phase III Clinical Trial of rhTNK-tPA in Treating Acute Ischemic Stroke With Extended Time Window. | 2027-09-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 59 studies testing tenecteplase in Ischemic Stroke, from their registry updates:
Among General Hospital of Shenyang Military Region’s 34 in Ischemic Stroke:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Despite being the standard pharmacological reperfusion therapy for acute ischemic stroke, intravenous thrombolysis is limited by suboptimal recanalization rates. Tenecteplase (TNK), a newer thrombolytic agent, offers practical advantages over alteplase, including single bolus administration. However, a significant proportion of patients fail to achieve early clinical improvement after standard thrombolysis, likely due to persistent vessel occlusion.
This study proposes to investigate a rescue strategy for patients who do not show significant neurological improvement within one hour after receiving standard intravenous tenecteplase within 3 hours of stroke onset. The primary objective is to evaluate the safety and feasibility of administering a second dose of tenecteplase in this scenario. The study will also explore the potential efficacy of this approach in improving recanalization and functional outcomes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tenecteplase is administered intravenously at a dose of 16 mg, with a maximum dose of 0.25 mg/kg.
Drug: Tenecteplase
No tenecteplase
Tenecteplase is administered intravenously at a dose of 16 mg, with a maximum dose of 0.25 mg/kg.
proportion of excellent functional outcome (modified Rankin Scale (mRS) 0-1)
The minimum and maximum values of mRS are 0 and 6, respectively; higher score mean a worse outcome
Time frame: 90±7 days
proportion of modified Rankin Scale (mRS) 0-2
The minimum and maximum values of mRS are 0 and 6, respectively; higher score mean a worse outcome
Time frame: 90±7 days
ordinal distribution of modified Rankin Scale (mRS)
The minimum and maximum values of mRS are 0 and 6, respectively; higher score mean a worse outcome
Time frame: 90±7 days
occurrence of early neurological improvement (ENI)
ENI is defined as more than 4-point decrease in National Institute of Health stroke scale score (NIHSS); the minimum and maximum values of NIHSS are 0 and 42, respectively; higher NIHSS mean a worse outcome
Time frame: 24 (-6/+12) hours
change in National Institute of Health stroke scale (NIHSS) score
the minimum and maximum values of National Institute of Health stroke scale (NIHSS) are 0 and 42, respectively; higher NIHSS score mean a worse outcome
Time frame: 24 (-6/+12) hours
change in National Institute of Health stroke scale (NIHSS) score
the minimum and maximum values of National Institute of Health stroke scale (NIHSS) are 0 and 42, respectively; higher NIHSS score mean a worse outcome
Time frame: 10±2 days
new stroke or other vascular event(s)
Time frame: 90±7 days
symptomatic intracranial hemorrhage (sICH)
Time frame: 24 (-6/+12) hours
any intracranial hemorrhage
Time frame: 24 (-6/+12) hours
major systemic bleeding event
Time frame: 24 (-6/+12) hours
any bleeding event
Time frame: 24 (-6/+12) hours
all-cause mortality
Time frame: 90±7 days
Started Mar 2026 (actual). Primary completion is estimated for Dec 2027, 21 months after the start.
Of 82 non-industry phase 2 interventional studies under Ischemic Stroke, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 40. This study's planned 21 months is below that.
Counting every sponsor, half of 123 studies reached it within 28 months; a quarter within 15 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tenecteplase
General Hospital of Shenyang Military Region